drugset
drugset / Trial / NCT04273815

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

NCT04273815 ↗

Phase 1/2 Unknown 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung cancer.

Timeline

Start
2020-07-06
Primary completion
2021-01-31
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ-A3334 Other / unclassified — Oral
Background Catequentinib Small molecule — Oral

Indications

non-small cell lung carcinoma